T. Rowe Price Investment Management Adds $969M in Ascendis Pharma A/S ($ASND)
Key Points
- T. Rowe Price Investment Management changed its Ascendis Pharma A/S ($ASND) stake by 269.5% last quarter, boosting to 6,162,042 shares worth $1.33 billion.
- Wall Street's consensus rating on $ASND is Strong Buy and an average price target of $296.75.
- $ASND last traded around $215.60.
T. Rowe Price Investment Management increased its position in Ascendis Pharma A/S ($ASND) by 269.5% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,162,042 shares of Ascendis Pharma A/S after buying 4,494,417 shares during the quarter. T. Rowe Price Investment Management's holdings in Ascendis Pharma A/S were worth $1.33 billion as of its most recent filing.
Ascendis Pharma A/S ($ASND) Stock
Ascendis Pharma A/S Earnings
Analysts Set New Price Targets
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.